See more : Alta Equipment Group Inc. (ALTG) Income Statement Analysis – Financial Results
Complete financial analysis of Marrone Bio Innovations, Inc. (MBII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marrone Bio Innovations, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Sichuan Changhong Electric Co.,Ltd. (600839.SS) Income Statement Analysis – Financial Results
- Shikibo Ltd. (3109.T) Income Statement Analysis – Financial Results
- Sparinvest Value Aktier KL (SPIVAKLA.CO) Income Statement Analysis – Financial Results
- Autins Group plc (AUTG.L) Income Statement Analysis – Financial Results
- Avanti Helium Corp. (ARGYF) Income Statement Analysis – Financial Results
Marrone Bio Innovations, Inc. (MBII)
About Marrone Bio Innovations, Inc.
Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.31M | 100.00K | 29.37M | 21.22M | 18.17M | 14.04M | 9.80M | 9.14M | 14.54M | 7.14M | 5.25M |
| Cost of Revenue | 17.06M | 40.00K | 13.26M | 10.91M | 10.53M | 9.52M | 9.26M | 9.44M | 10.74M | 4.33M | 2.17M |
| Gross Profit | 27.25M | 60.00K | 16.11M | 10.31M | 7.64M | 4.52M | 545.00K | -302.00K | 3.81M | 2.81M | 3.08M |
| Gross Profit Ratio | 61.49% | 60.00% | 54.86% | 48.60% | 42.05% | 32.19% | 5.56% | -3.31% | 26.18% | 39.31% | 58.64% |
| Research & Development | 12.08M | 30.00K | 14.03M | 10.66M | 10.82M | 9.67M | 13.50M | 19.28M | 17.81M | 12.74M | 9.41M |
| General & Administrative | 0.00 | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.57M | 75.00K | 30.07M | 19.16M | 19.81M | 18.51M | 26.50M | 28.95M | 15.02M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.29M | 6.79M |
| Operating Expenses | 42.65M | 105.00K | 44.10M | 29.82M | 30.63M | 28.18M | 40.00M | 48.23M | 32.83M | 23.04M | 16.20M |
| Cost & Expenses | 59.71M | 145.00K | 57.36M | 40.72M | 41.16M | 37.70M | 49.26M | 57.67M | 43.57M | 27.37M | 18.38M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 37.00K | 51.00K | 59.00K | 49.00K | 16.00K | 22.00K |
| Interest Expense | 1.57M | 4.00K | 1.47M | 2.51M | 7.73M | 7.30M | 4.36M | 2.91M | 6.00M | 2.47M | 88.00K |
| Depreciation & Amortization | 4.57M | 3.56M | 3.15M | 1.89M | 2.04M | 2.24M | 3.51M | 2.58M | 976.00K | 613.00K | 499.00K |
| EBITDA | -10.37M | 3.51M | -32.53M | -15.82M | -21.15M | -21.53M | -35.86M | -46.17M | -21.52M | -35.72M | -12.59M |
| EBITDA Ratio | -23.41% | 3,509.00% | -110.75% | -74.53% | -116.43% | -153.35% | -365.83% | -505.37% | -147.95% | -500.21% | -239.82% |
| Operating Income | -14.94M | -17.20M | -27.99M | -19.50M | -23.00M | -23.66M | -39.46M | -48.53M | -29.03M | -23.84M | -13.12M |
| Operating Income Ratio | -33.71% | -17,195.00% | -95.27% | -91.91% | -126.58% | -168.49% | -402.58% | -531.23% | -199.58% | -333.87% | -249.93% |
| Total Other Income/Expenses | -1.57M | 17.14M | -9.19M | -709.00K | -7.93M | -7.41M | -4.27M | -3.13M | 536.00K | -14.96M | -56.00K |
| Income Before Tax | -16.51M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Income Before Tax Ratio | -37.26% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| Income Tax Expense | 45.00K | 17.15M | 15.00K | 1.80M | -201.00K | -109.00K | 92.00K | -219.00K | 6.53M | -12.49M | 32.00K |
| Net Income | -16.55M | -53.00K | -37.18M | -20.21M | -30.93M | -31.07M | -43.73M | -51.66M | -28.49M | -38.79M | -13.18M |
| Net Income Ratio | -37.36% | -53.00% | -126.56% | -95.25% | -170.23% | -221.27% | -446.16% | -565.44% | -195.89% | -543.33% | -251.00% |
| EPS | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.26 | -2.12 | -0.72 |
| EPS Diluted | -0.09 | 0.00 | -0.32 | -0.20 | -1.06 | -1.26 | -1.79 | -2.32 | -3.20 | -2.12 | -0.72 |
| Weighted Avg Shares Out | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.73M | 18.27M | 18.27M |
| Weighted Avg Shares Out (Dil) | 174.83M | 148.89M | 117.98M | 101.25M | 29.24M | 24.62M | 24.47M | 22.31M | 8.91M | 18.27M | 18.27M |
7 Penny Stocks to Book Profits on Before 2022
Marrone Bio (MBII) Q3 Earnings In Line, Revenues Lag Estimates
Marrone Bio Innovations' (MBII) CEO Kevin Helash on Q3 2021 Results - Earnings Call Transcript
Marrone Bio Innovations, Inc. (MBII) Reports Q3 Loss, Misses Revenue Estimates
Marrone Bio Innovations, Inc. Reports Third-Quarter 2021 Financial Results
Marrone Bio Innovations Receives Nasdaq Notice Regarding Failure to Satisfy a Continued Listing Rule
Marrone Bio Submits Regulatory Packages for Nematicides/Insecticides in United States and Brazil
Marrone Bio Prepares to Submit Registration for Next-Generation Crop Protection Product in North America
Marrone (MBII) & Terramera Partner to Boost Crop Protection
Marrone Bio (MBII) Q2 Earnings and Revenues Miss Estimates
Source: https://incomestatements.info
Category: Stock Reports